Crossmark

ASO Author Reflections: Minimally Invasive Inguinal Lymphadenectomy, an Incremental Step in the Evolution of the Management of Advanced Melanoma

Published Online: 2022-04-30

Published Print: 2022-09

Authors

Jakub, James W. https://orcid.org/0000-0002-8005-1072
Faries, Mark B.
License Information

Text and Data Mining valid from 2022-04-30

Version of Record valid from 2022-04-30
More Information

Article History

Received: 19 April 2022

Accepted: 20 April 2022

First Online: 30 April 2022

Disclosures

: James Jakub: Novartis Melanoma Surgical Oncology Advisory Board, Sorrento Therapeutics. Mark Faries: Advisory Boards for Novartis, Bristol Myers Squibb, Merck, Pulse Bioscience, Array Bioscience, Sanofi.

Document is current